Latest H5N1 clinical trials Stories
SWIFTWATER, Pa., Oct.
ATLANTA, Oct. 18 /PRNewswire/ -- Robert T. McNally, Ph.D., president and CEO of GeoVax Labs, Inc.
SWIFTWATER, Pa., Oct. 8 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), has been awarded a three-year contract for $56.94 million by the U.S.
LA JOLLA, Calif., Oct. 7 /PRNewswire/ -- The company Synthetic Genomics Inc. (SGI) and the not-for-profit research organization, the J. Craig Venter Institute (JCVI) today announced the formation of a new company, Synthetic Genomics Vaccines Inc. (SGVI).
GAITHERSBURG, Md., Oct. 6 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that SAIC-Frederick, Inc.
ATLANTA, Oct. 1 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc.
An experimental vaccine intended to prevent genital herpes disease in women, although generally safe and well-tolerated, proved ineffective when tested in the recently concluded clinical study known as the Herpevac Trial for Women.
LYON, France, September 27, 2010 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY) announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S.
ATLANTA, Sept. 27 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc.
WORCESTER, Mass., Sept. 16 /PRNewswire/ -- Generex Biotechnology Corporation (NasdaqCM: GNBT; www.generex.com) today announced presentations in respect of the technologies and development products of its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).